Literature DB >> 29497133

Bilateral acute iris transillumination following systemic administration of antibiotics.

Paris Tranos1, Evangelos Lokovitis2, Stelios Masselos3, Nikolaos Kozeis1, Magda Triantafylla1, Nikolaos Markomichelakis3.   

Abstract

OBJECTIVES: To describe the demographic characteristics, clinical features, and potential prognostic factors of bilateral acute iris transillumination (BAIT) following oral antibiotic uptake.
METHODS: A retrospective study of 16 consecutive patients who developed BAIT following treatment with systemic antibiotics. Detailed past medical and ocular history was obtained, presenting signs and symptoms were documented and demographic characteristics were analyzed. All patients underwent a complete ocular examination and laboratory investigation. The course of best corrected visual acuity (BCVA), anterior chamber activity, and intraocular pressure (IOP) during the follow-up period were recorded and possible correlations with potential prognosticators were investigated.
RESULTS: Fourteen females and two males were included in the present study. The mean age (SD) of the patients was 43 (14) years. All individuals presented conjunctival injection and photophobia and developed bilateral transillumination defects, fixed mid-dilated pupils and pigment dispersion in the anterior chamber. Systemic antibiotics were previously prescribed in all cases (13 patients with moxifloxacin and three patients with clarithromycin) and the mean (SD) interval between onset of symptoms and antibiotic administration was 17 (4) days. Ocular hypertension complicated all eyes and required antiglaucoma medication in 25 eyes. Severe anterior chamber pigment dispersion and higher IOP during the first week after presentation was significantly associated with longer duration of ocular hypertension (OHT) (p = 0.019).
CONCLUSIONS: BAIT represents a rare clinical entity with characteristic features. Although etiopathogenesis of this condition remains unclear, a series of cases that indicate a strong correlation between systemic antibiotic administration and BAIT is herein presented.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29497133      PMCID: PMC6043476          DOI: 10.1038/s41433-018-0054-y

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  23 in total

Review 1.  Varicella-zoster virus eye disease.

Authors:  T J Liesegang
Journal:  Cornea       Date:  1999-09       Impact factor: 2.651

2.  Bilateral acute depigmentation of the iris.

Authors:  Ilknur Tugal-Tutkun; Meri Urgancioglu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-05       Impact factor: 3.117

3.  Bilateral uveitis associated with fluoroquinolone therapy.

Authors:  David M Hinkle; Mark S Dacey; Efrem Mandelcorn; Partho Kalyani; John Mauro; James H Bates; Sarkis H Soukasian; Gary N Holland; C Stephen Foster; Frederick T Fraunfelder; Janet L Davis; Frederick W Fraunfelder
Journal:  Cutan Ocul Toxicol       Date:  2011-10-08       Impact factor: 1.820

4.  Acute primary ischemic iris atrophy.

Authors:  A M Brooks; R H West; W E Gillies
Journal:  Ophthalmology       Date:  1988-09       Impact factor: 12.079

5.  Vitreous and aqueous penetration of orally and topically administered moxifloxacin.

Authors:  Masamichi Fukuda; Naoko Shibata; Hiromi Osada; Yoko Yamashiro; Hiroshi Sasaki
Journal:  Ophthalmic Res       Date:  2011-02-12       Impact factor: 2.892

Review 6.  Bilateral acute iris transillumination following systemic moxifloxacin for respiratory illness: report of two cases and review of the literature.

Authors:  R Grant Morshedi; Daniel I Bettis; Majid Moshirfar; Albert T Vitale
Journal:  Ocul Immunol Inflamm       Date:  2012-06-13       Impact factor: 3.070

Review 7.  Pigment dispersion syndrome and pigmentary glaucoma--a major review.

Authors:  Nuwan Niyadurupola; David C Broadway
Journal:  Clin Exp Ophthalmol       Date:  2008-12       Impact factor: 4.207

8.  [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application].

Authors:  M Kernt; C Hirneiss; A S Neubauer; R G Liegl; K H Eibl; A Wolf; H de Kaspar; M W Ulbig; A Kampik
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

9.  Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin.

Authors:  M Wefers Bettink-Remeijer; K Brouwers; L van Langenhove; P W T De Waard; T O Missotten; J P Martinez Ciriano; E Van Aken
Journal:  Eye (Lond)       Date:  2009-12       Impact factor: 3.775

10.  Bilateral diffuse iris atrophy after the use of oral clarithromycin.

Authors:  Paris Tranos; Mayssa B Nasr; Solon Asteriades; Athanasios Vakalis; Ilias Georgalas
Journal:  Cutan Ocul Toxicol       Date:  2013-06-14       Impact factor: 1.820

View more
  1 in total

1.  Bilateral acute anterior uveitis and iris atrophy caused by moxifloxacin.

Authors:  Benjamin Tsun Kiu Hui; Nicholas Capewell; Yousuf Ansari; Xiaoxuan Liu
Journal:  BMJ Case Rep       Date:  2020-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.